ACB:NSD-Aurora Cannabis Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 2.57

Change

-0.17 (-6.20)%

Market Cap

USD 0.62B

Volume

5.48M

Avg Analyst Target

USD 7.00 (+172.37%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

Aurora Cannabis Inc (ACB) Stock Analysis:
Based on the Aurora Cannabis Inc stock forecasts from 4 analysts, the average analyst target price for Aurora Cannabis Inc is USD 7.00 over the next 12 months. Aurora Cannabis Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Aurora Cannabis Inc is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, Aurora Cannabis Inc’s stock price was USD 2.57. Aurora Cannabis Inc’s stock price has changed by -16.83% over the past week, -15.74% over the past month and -66.23% over the last year.

About

Aurora Cannabis Inc. produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail dist ...Read More

Company Website : https://www.auroramj.com

Address : 500 - 10355 Jasper Avenue, Edmonton, AB, Canada, T5J 1Y6

Employees : 1,761

Fiscal Year End : June

Currency: USD

Country : USA

Technical Indicators

Beta : 3.10

52 Week High : 10.64

Short Ratio : 3.98

52 Week Low : 2.20

Shorted Shares : 28,004,254

200 Day Moving Average : 5.35

Shorted Shares Previous Month : 26,655,776

50 Day Moving Average : 3.32

Shares Held By Insiders : 0.04%

Short Percentage : 20.42%

Shares Held by Institutions : 19.69%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-24 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

 USD8.59B 30.73 11.86
NBIX Neurocrine Biosciences Inc

-1.89 (-2.19%)

 USD8.24B 118.05 62.27
APHA Tilray, Inc

N/A

 USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

 USD6.24B N/A N/A
ITCI Intra-Cellular Therapies Inc

-1.45 (-2.48%)

 USD5.46B N/A N/A
PCRX Pacira BioSciences Inc

-2.46 (-3.90%)

 USD2.89B 75.79 27.19
TLRY Tilray Inc

-0.23 (-5.12%)

 USD2.35B 49.17 N/A
CGC Canopy Growth Corporation

-0.43 (-8.29%)

 USD2.32B N/A N/A
IRWD Ironwood Pharmaceuticals Inc

-0.30 (-2.64%)

 USD1.75B 3.70 6.95
AMPH Amphastar Pharmaceuticals Inc

-0.86 (-2.47%)

 USD1.70B 21.47 11.51

ETFs Containing ACB

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -52.50% 47% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -52.50% 47% F 23% F
Trailing 12 Months  
Capital Gain -68.15% 51% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -68.15% 51% F 21% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 79.32% 94% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 79.32% 94% A 93% A
Risk Return Profile  
Volatility (Standard Deviation) 272.85% 7% F 5% F
Risk Adjusted Return 29.07% 79% C+ 57% F
Market Capitalization 0.62B 77% C+ 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 43.15 31% F 22% F
Price/Book Ratio 0.44 89% B+ 95% A
Price / Cash Flow Ratio -2.95 69% D+ 65% D
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -75.46% 43% F 16% F
Return on Invested Capital -11.14% 69% D+ 36% F
Return on Assets -6.25% 64% D 34% F
Debt to Equity Ratio 14.39% 65% D 68% D+
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 3.98 56% F 41% F
Short Percent 20.42% 7% F 8% F
Beta 3.10 6% F 2% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

New Post

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector